Description
Vernon Press Borders and Beyond Orient-Occident Crossings in Literature 2018 Edition by Adam Bednarczyk
The work presents articles discussing various subjects relating to literary, cultural borders and borderlands as well as their crossings with the Orient and the Occident. A broad, multifaceted scope of the volume draws the attention of readers to the problem of liminal spaces between cultures, genres, codes and languages of literary and artistic communication. The perspective of borderness proposed by orientalists, literary specialists, culture experts provide insights into multi-dimensional and heterogenic subjects and methods of consideration. The authors referring to, inter alia, comparative studies, theory of reception, intertextuality, transculturality of the East and West works touch upon themes such as coexistence, exclusion, crossing or the instability of borders. Also by taking into account identity issues, the interpenetration of various influences between different literatures, poetics and languages, the readers gain a broader context of intercultural dialogue between the Orient and Occident, what allow them to transgress barriers of a purely artistic, literary reception of the book contents. The volume - due to the abundance of proposed topics, its heterogeneous representations and manifold approaches used in analysis, discussion and (re)interpretations - is a debate's record or a result of an academic reflection rather than a comprehensive monograph. Table of contents : - 1. Introduction and disease overviewReferences2. Incretin hormones as a target for therapyIncretin hormone physiology The incretin-producing cellGIP and GLP-1 actionMeasurement of the incretin hormonesIncretin action in healthy individualsIncretin action in patients with type 2 diabetesTherapeutics applicationReferences3. Glucagon-like peptide receptor agonists Introduction GLP-1 receptor agonists Extrapancreatic effects GLP-1 receptor agonists Pancreatic safety Perspectives References 4. Dipeptidyl peptidase-4 inhibitors Introduction Pharmacokinetics and pharmacodynamics Efficacy Combination therapy Use in specific patient populations Conclusions References 5. Global position and recommendations for use Introduction American Association of Clinical Endocrinologists/American College of EndocrinologyAmerican Diabetes Association /European Association for the Study of DiabetesInternational Diabetes Federation National Institute of Health and Care Excellence Using incretin-based therapies in clinical practice Availability and licences References 6. Future and emerging therapies Introduction Once-weekly agents under investigation Subcutaneous implants Investigational DPP-4 inhibitors and fixed-dose combination with SGLT2 inhibitors Other indications for incretin therapiesDPP-4 inhibitorsReferences